Ascentage Pharma Group International is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of small-molecule therapies that restore protein homeostasis to treat cancer and other serious diseases. Founded in 2004 and headquartered in Suzhou, China, Ascentage has built a diverse pipeline of novel drug candidates targeting pathways involved in cell apoptosis, senescence and metabolic regulation.
The company’s lead programs focus on inhibitors of the MDM2–p53 interaction and selective antagonists of the Bcl-2 family of proteins, both of which are critical regulators of programmed cell death. Ascentage’s MDM2 inhibitor, currently in Phase 1/2 trials, is designed to reactivate the p53 tumor suppressor in cancers that retain wild-type p53, while its Bcl-2/Bcl-xL dual inhibitor has shown promise in preclinical studies of hematological malignancies and solid tumors. In addition, Ascentage is advancing senolytic agents that aim to clear dysfunctional cells in age-related diseases such as nonalcoholic steatohepatitis (NASH). These programs reflect the company’s broader strategy of addressing unmet medical needs through precision targeting of key disease pathways.
Ascentage operates research and development centers in Suzhou, Shanghai and San Diego, leveraging a global network of scientific collaborations and strategic partnerships. The company has entered co-development agreements with leading multinational pharmaceutical firms to accelerate clinical development and expand geographic reach. Ascentage’s integrated approach combines in-house medicinal chemistry, translational biology and biomarker-driven trial designs to optimize candidate selection and support regulatory filings across multiple regions, including Greater China, North America and Southeast Asia.
Under the leadership of founder and Chief Executive Officer Doctor Wenguang Wang, Ascentage is governed by a management team with deep experience in drug discovery, clinical development and international commercialization. The board includes seasoned industry executives and academic advisors who guide the company’s strategic priorities and ensure rigorous oversight of scientific and operational milestones. Ascentage continues to leverage its proprietary platforms to advance novel therapies that may offer durable benefits for patients living with cancer and other challenging diseases.
AI Generated. May Contain Errors.
Free AAPG Stock Alerts